Alvotech (Alvotech) Other Gross PPE : $362.83 Mil (As of Mar. 2024)

View and export this data going back to 2022. Start your Free Trial

What is Alvotech Other Gross PPE?

Alvotech's Other Gross PPE for the quarter that ended in Mar. 2024 was $362.83 Mil.

Alvotech's quarterly Other Gross PPE declined from Sep. 2023 ($343.46 Mil) to Dec. 2023 ($119.41 Mil) but then increased from Dec. 2023 ($119.41 Mil) to Mar. 2024 ($362.83 Mil).

Alvotech's annual Other Gross PPE declined from Dec. 2021 ($126.64 Mil) to Dec. 2022 ($47.16 Mil) but then increased from Dec. 2022 ($47.16 Mil) to Dec. 2023 ($119.41 Mil).

Alvotech Other Gross PPE Historical Data

The historical data trend for Alvotech's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Alvotech Other Gross PPE Chart

Alvotech Annual Data

Trend

Dec19

Dec20

Dec21

Dec22

Dec23

Other Gross PPE

111.49

126.64

47.16

119.41

Alvotech Quarterly Data
	Dec19	Dec20	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Other Gross PPE	Get a 7-Day Free Trial									272.32	333.39	343.46	119.41	362.83

Alvotech Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Alvotech (Alvotech) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Alvotech (NAS:ALVOW) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

ALVO:USA ALVO:Iceland Z45:Germany

Address

9, rue de Bitbourg, Luxembourg, LUX, L-1273

Website

https://www.alvotech.com

Alvotech is an integrated biopharmaceutical company committed to developing and manufacturing high-quality biosimilar medicines for patients globally. its purpose is to improve the health and quality of life of patients around the world by improving access to proven treatments for various diseases.